Skin, and nail, infections associated with the addition of pertuzumab to trastuzumab-based chemotherapy

被引：1
|
作者：
Mortimer, J. E. [1 ]
Yuan, Y. [1 ]
Jung, J. [1 ]
Kruper, L. [1 ]
Stewart, D. [1 ]
Chung, S. [1 ]
Yu, W. K. [1 ]
Mendelsohn, M. [1 ]
D'Apuzzo, M. [1 ]
Tegtmeier, B. [1 ]
Dadwal, S. [1 ]
机构：
[1] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P1-10-19
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-10-19
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer
    van Ramshorst, Mette S.
    van der Heiden-van der Loo, Margriet
    Dackus, Gwen M. H. E.
    Linn, Sabine C.
    Sonke, Gabe S.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (02) : 361 - 371
  • [42] The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer
    Mette S. van Ramshorst
    Margriet van der Heiden-van der Loo
    Gwen M. H. E. Dackus
    Sabine C. Linn
    Gabe S. Sonke
    Breast Cancer Research and Treatment, 2016, 158 : 361 - 371
  • [43] Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer
    Mette S. van Ramshorst
    Margriet van der Heiden-van der Loo
    Gwen M. H. E. Dackus
    Sabine C. Linn
    Gabe S. Sonke
    Breast Cancer Research and Treatment, 2016, 159 : 393 - 393
  • [44] Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer
    Costa, R. B.
    Kurra, G.
    Greenberg, L.
    Geyer, C. E.
    ANNALS OF ONCOLOGY, 2010, 21 (11) : 2153 - 2160
  • [45] Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy
    Esther Schmitt
    Frédérique Végran
    Sandy Chevrier
    Laura Burillier
    Muriel Cadouot
    Sarab Lizard-Nacol
    Bruno Coudert
    Pierre Fumoleau
    Laurent Arnould
    Romain Boidot
    BMC Cancer, 15
  • [46] Quantifying the benefit of the addition of pertuzumab to standard neoadjuvant chemotherapy plus trastuzumab for HER 2 positive breast cancer: The experience of a single oncology unit
    Kong, Jun Beng
    Thomson, Jacqui
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 125 - 126
  • [47] Meta-analysis Evaluating the Use of Statins to attenuate Cardiotoxicity in Cancer Patients receiving Anthracyclines and Trastuzumab-based Chemotherapy
    Shahid, Izza
    Yamani, Naser
    Ali, Abraish
    Kumar, Pankaj
    Figueredo, Vincent
    Unzek, Samuel
    Mookadam, Farouk
    AMERICAN JOURNAL OF CARDIOLOGY, 2021, 156 : 142 - 145
  • [48] PROGNOSTIC IMPACT OF HER2 IMMUNOREACTIVITY IN HER2-POSITIVE GASTRIC CANCER TREATED WITH TRASTUZUMAB-BASED CHEMOTHERAPY
    Kadowaki, Shigenori
    Narita, Yukiya
    Komori, Azusa
    Nomura, Motoo
    Taniguchi, Hiroya
    Takahari, Daisuke
    Ura, Takashi
    Andoh, Masashi
    Niwa, Yasumasa
    Muro, Kei
    ANNALS OF ONCOLOGY, 2014, 25
  • [49] Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel plus trastuzumab-based neoadjuvant chemotherapy
    Schmitt, Esther
    Vegran, Frederique
    Chevrier, Sandy
    Burillier, Laura
    Cadouot, Muriel
    Lizard-Nacol, Sarab
    Coudert, Bruno
    Fumoleau, Pierre
    Arnould, Laurent
    Boidot, Romain
    BMC CANCER, 2015, 15
  • [50] Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial
    Conte, Benedetta
    Montemurro, Filippo
    Levaggi, Alessia
    Blondeaux, Eva
    Molinelli, Chiara
    Cardinali, Barbara
    Poggio, Francesca
    Buzzatti, Giulia
    Bighin, Claudia
    Lambertini, Matteo
    Del Mastro, Lucia
    TUMORI JOURNAL, 2023, 109 (01): : 71 - 78
12345